In our system, however, RNAi-mediated depletion of p53 using a lentiviral vector encoding for shRNA directed against p53 abrogated the tozasertib- and alisertib-induced p53 response (Figure 3B) and reduced neuroblastoma sensitivity to tozasertib and alisertib (Figure 3C). The gene discussed is TP53; the disease is neuroblastoma.